As adenine base editing moves from laboratory promise toward clinical reality, the question of unintended consequences has grown too urgent to leave to prediction alone. Broken String Biosciences has answered with BaseMap ABE, a platform that observes off-target editing events directly in living cells rather than modeling them from a distance. Launched in August 2026, the tool arrives at a moment when the gap between scientific elegance and patient safety demands something more than a best guess — it demands evidence.